Antidepressant makers ordered to cite suicidal risk in labeling+
Welcome to TMCnet.com
TMC Launches New Sites: Cable 4G Wireless Evolution  |  Satellite  |  Green Tech  | IT | IVR |  ITEXPO East begins in:   REGISTER NOW!
Columnists:
E-mail this page to a friend Order reprints online Print this page Bookmark this page Free magazines Free newsletters RSS-XML alerts
Digg this article!

[February 08, 2006]

Antidepressant makers ordered to cite suicidal risk in labeling+

(Japan Economic Newswire Via Thomson Dialog NewsEdge)TOKYO, Feb. 9_(Kyodo) _ The health ministry has ordered drugmakers to revise the labeling for their antidepressant drugs to include a warning on an increased risk of suicide, the first order of its kind in Japan, according to ministry officials.



Twelve types of drugs will be subject to the measure, the officials told Kyodo News, adding that they include not only the group of antidepressants known as selective serotonin reuptake inhibitors, or SSRIs, which are known to trigger suicidal behavior among minors, but also nearly all antidepressant drugs prescribed by doctors.

In October 2004, the U.S. Food and Drug Administration ordered all manufacturers of antidepressant drugs to revise the labeling to include greater warnings that alert healthcare providers to an increased risk of suicidal thinking and behavior.



Because the drugs are administered differently in Japan than in Europe and the United States, the Ministry of Health, Labor and Welfare worked to revise the labeling based on an investigation by the Pharmaceuticals and Medical Devices Agency, an independent administrative organization to help people suffering from side effects even though they have used drugs correctly.

The drugs affected by the measure include Paxil (paroxetine hydrochloride), Tofranil (imipramine hydrochloride) and Toledomin (milnacipran hydrochloride).

Increasing cases of abuse of antidepressants, often dubbed "happy drugs," among minors, have become a social problem in Europe and the United States.

The ministry has requested that the manufacturers clearly state in the labeling that users must exercise caution when administering the drugs because they are associated with an increased risk of suicidal thoughts among people diagnosed with depression.

According to the FDA, suicidal tendencies have doubled among minors using the SSRIs and other types of antidepressant drugs. In 2002, antidepressants were prescribed to about 11 million children in the United States.

"Doctors have prescribed antidepressant drugs carefully because depression sufferers have a tendency to plan suicides," said an official at the Pharmaceutical and Food Safety Bureau's Safety Division of the ministry.

"The revision is not likely to cause a major change in the medical field, but it is necessary to call for an even greater warning," the official added.

[ Back To TMCnet.com's Homepage ]


Digg this article!

Discussions:
Be the first to post a comment on this page!
 
By  
TMCnet

E-mail this page to a friend Order reprints online Print this page Bookmark this page Free magazines Free newsletters RSS-XML alerts


Today @ TMC
Upcoming Events
19th INTERNET TELEPHONY Conference & EXPO East
February 2-4, 2009 — Miami Beach Convention Center, Miami, FL
Digium Asterisk World Conference
February 2-4, 2009 — Miami Beach Convention Center, Miami, FL
4G Wireless Evolution Conference
February 2-4, 2009 — Miami Beach Convention Center, Miami, FL
6th Annual Communications Developer Conference
February 2-4, 2009 — Miami Beach Convention Center, Miami, FL
20th INTERNET TELEPHONY Conference & EXPO West
October 27-29, 2009 — Los Angeles Convention Center, Los Angeles, CA
Subscribe FREE to all of TMC's monthly magazines. Click here now.
TMC LOGO
Technology Marketing Corporation,
One Technology Plaza, Norwalk, CT 06854 USA
Ph: 800-243-6002, 203-852-6800; Fx: 203-866-3326
General comments: tmc@tmcnet.com. Comments about this site: webmaster@tmcnet.com.
About   Contact  Advertise
Technology Marketing Corp. 1997-2008 Copyright. Privacy Policy Sitemap
Advanced